NASDAQ:AKTS Aktis Oncology Q1 2026 Earnings Report $19.48 -0.15 (-0.74%) Closing price 03:59 PM EasternExtended Trading$19.48 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aktis Oncology EPS ResultsActual EPS-$0.38Consensus EPS -$0.37Beat/MissMissed by -$0.01One Year Ago EPSN/AAktis Oncology Revenue ResultsActual Revenue$3.23 millionExpected Revenue$2.23 millionBeat/MissBeat by +$997.00 thousandYoY Revenue GrowthN/AAktis Oncology Announcement DetailsQuarterQ1 2026Date5/11/2026TimeBefore Market OpensConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETUpcoming EarningsAktis Oncology's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aktis Oncology Earnings HeadlinesAktis Oncology, Inc.(NasdaqGS:AKTS) added to S&P Biotechnology Select Industry IndexSeptember 21, 2026 | marketscreener.comMCritical Analysis: Aktis Oncology (NASDAQ:AKTS) versus Rigel Pharmaceuticals (NASDAQ:RIGL)September 21, 2026 | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 25 at 1:00 AM | Banyan Hill Publishing (Ad)Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comOppenheimer Initiates Coverage on Akoustis Technologies With Outperform Rating, $40 PTSeptember 9, 2026 | marketscreener.comMAktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush SaysAugust 19, 2026 | finance.yahoo.comSee More Aktis Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aktis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aktis Oncology and other key companies, straight to your email. Email Address About Aktis OncologyAktis Oncology (NASDAQ:AKTS), Inc. is a clinical-stage biotechnology company focused on developing precision cancer treatments. The company’s research is centered on targeted alpha therapies, which are designed to deliver highly potent radiation directly to cancer cells while limiting exposure to surrounding healthy tissue. Aktis Oncology is developing a pipeline of investigational therapies for solid tumors and other cancers. Its programs are intended to use tumor-targeting molecules to selectively transport radioactive payloads to cancer cells, with the goal of improving treatment effectiveness and addressing cancers that may be difficult to treat with conventional approaches. The company’s product candidates remain in development and are subject to clinical, regulatory and commercial risks. Publicly available information about Aktis Oncology’s leadership, geographic operations and commercial products is limited.View Aktis Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
